fbpx
  • Home
  • Study Details
Not currently enrolling

Finch CDI-001 Prism 3

The purpose of this research study is to evaluate effectiveness and potential side effects of taking the test medicine versus a placebo to prevent recurrent Clostridium difficile infection (CDI). The test medicine, CP101, has not been approved by the FDA to treat or prevent recurrent CDI; its use in this study is investigational. By comparing people's responses to the placebo and to the test medicine being studied, researchers can tell whether the test medicine is having any benefit to prevent recurrent CDI.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Sarah McGill
Medicine-Gastroenterology

Study Topics

Stomach, Digestion and Gut Health
Microbiome

IRB Number

18-1684

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.